Novartis adds regenerative liver disease program to pipeline via Alnylam deal

Novartis is expanding its pipeline in end-stage liver disease via a deal with Alnylam, the first announced under the watch of new CEO Yvonne Greenstreet.

The three-year collaboration announced Thursday will use the RNAi platform from Alnylam Pharmaceuticals inc. (NASDAQ:ALNY) to develop siRNA candidates against an undisclosed target discovered by the Novartis Institutes for BioMedical Research (NIBR) at Novartis AG (NYSE:NVS; SIX:NOVN) to restore functional hepatocytes in patients with ESLD...